top of page

Alcobra Pharmaceuticals

Treatment of Cognitive Disorders

Company Name
Updating Date
Neurotech Category
Market Category
Target Market
Company Founded Year
Company Number of Employees
Alcobra Pharmaceuticals
Biotechnology & Biopharmaceutical
Go to company site

Alcobra Pharmaceuticals is an emerging pharmaceutical company primarily focused on the development and commercialization of a proprietary drug, Metadoxine Extended Release (MDX), designed to treat cognitive disorders including attention-deficit/hyperactivity disorder (ADHD) and Fragile X syndrome.

MDX is not a stimulant and works through a different mechanism of action than other ADHD treatments. Alcobra has completed multiple phase 2 studies and a phase 3 study of MDX in adults with ADHD. The company is conducting separate phase 2b trials of MDX in patients with pediatric ADHD and Fragile X syndrome.

In 2017, six months after Alcobra’s clinical trial of its main product for treating attention disorders failed, the company announced its intention to merge with Arcturus Therapeutics Inc of San Diego.

bottom of page